Counsyl has begun offering a next-generation sequencing-based expanded carrier screening test to early access users with a full commercial launch planned for the end of the second quarter this year.

The test complements Counsyl's array-based genotyping test, which screens for around 400 variants in 100 disorders. The sequencing-based test screens for the same disorders, but can detect over 10,000 mutations.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.